Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens ; volume:59 ; number:12 ; day:27 ; month:9 ; year:2024 ; pages:1744-1753 ; date:12.2024
Bone marrow transplantation ; 59, Heft 12 (27.9.2024), 1744-1753, 12.2024
- Urheber
-
Duque Afonso, Jesús
Rassner, Paraschiva
Walther, Kristin
Ihorst, Gabriele
Wehr, Claudia
Marks, Reinhard
Wäsch, Ralph
Bertz, Hartmut
Köhler, Thomas
Frye, Björn Christian
Stolz, Daiana
Zeiser, Robert
Finke, Jürgen
Maas-Bauer, Kristina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41409-024-02422-z
- URN
-
urn:nbn:de:101:1-2502162126381.415003278923
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Duque Afonso, Jesús
- Rassner, Paraschiva
- Walther, Kristin
- Ihorst, Gabriele
- Wehr, Claudia
- Marks, Reinhard
- Wäsch, Ralph
- Bertz, Hartmut
- Köhler, Thomas
- Frye, Björn Christian
- Stolz, Daiana
- Zeiser, Robert
- Finke, Jürgen
- Maas-Bauer, Kristina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens
Response to daratumumab-retreatment in patients with multiple myeloma
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
Clinical characteristics, cytogenetic risks, and prognoses of young multiple myeloma patients in the era of novel therapies
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
Osteoprotective medication in the era of novel agents : : a european perspective on values, risks and future solutions
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort
Plasma cell leukemia: another piece of the puzzle
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens
Response to daratumumab-retreatment in patients with multiple myeloma
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
Clinical characteristics, cytogenetic risks, and prognoses of young multiple myeloma patients in the era of novel therapies
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
Osteoprotective medication in the era of novel agents : : a european perspective on values, risks and future solutions
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort
Plasma cell leukemia: another piece of the puzzle
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens
Response to daratumumab-retreatment in patients with multiple myeloma
Risk of disease recurrence and survival in patients with multiple myeloma: A German Study Group analysis using a conditional survival approach with long‐term follow‐up of 815 patients
Clinical characteristics, cytogenetic risks, and prognoses of young multiple myeloma patients in the era of novel therapies
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
Osteoprotective medication in the era of novel agents : : a european perspective on values, risks and future solutions
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT
Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort